Naproxen Suppositories

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>DIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naproxen 500mg Supp</td>
<td>PMS</td>
<td>0217237</td>
</tr>
</tbody>
</table>

PMS-naproxen 500mg suppositories are no longer available. Although not officially discontinued, they have been inactivated and there are no plans to manufacture this product in the near future.\(^1\)

No other brands are available.\(^2,3\)

Naproxen suppositories are primarily used when NSAIDs cannot be taken or tolerated orally or when their local effects are desired, for example, in postpartum pain and postoperatively.\(^4,5\) They are also indicated for reducing incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis (ERCP).\(^6\)

Other NSAIDs available in rectal suppository form:\(^2,3,7,9\)

<table>
<thead>
<tr>
<th>Strength</th>
<th>Manufacturers</th>
<th>Recommended Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mg</td>
<td>SDZ</td>
<td>Max daily dose: 100mg-200mg</td>
<td>Increased incidence of adverse effects e.g. headache, drowsiness, dizziness - particularly in geriatrics(^2,8)</td>
</tr>
<tr>
<td>100 mg</td>
<td>SDZ</td>
<td>100mg max/dose(^2)</td>
<td></td>
</tr>
<tr>
<td>50 mg</td>
<td>PMS, SDZ, NVR (Voltaren(^\circledast))</td>
<td>50-100mg OD</td>
<td>Risk of myocardial infarction and stroke may be higher than with naproxen. Most commonly associated with hepatic adverse drug reactions.(^2)</td>
</tr>
<tr>
<td>100 mg</td>
<td>PMS, SDZ, NVR (Voltaren(^\circledast))</td>
<td>Max daily dose: 100mg</td>
<td></td>
</tr>
</tbody>
</table>

*All preparations are on the Saskatchewan Drug Plan & Extended Benefits Branch\(^8\) and Non-Insured Health Benefits\(^9\) formularies.

Prepared by D. Sanderson BSP, reviewed by K. Jensen MSC, BSP and C. Bell BSP
